Alternate Title: Distribution characteristics of microsatellites in the whole genome of Acer yangbiense. (English)

المؤلفون: 史雯茜, 马秋月, 陈梓馨, 李倩中, 李淑娴, 李淑顺, 朱长虹, 朱 璐, 颜坤元, 杜一鸣

المصدر: Journal of Central South University of Forestry & Technology; 2024, Vol. 44 Issue 12, p178-186, 9p

المؤلفون: 顏坤仁

Thesis Advisors: 康淑珍

وصف الملف: 49

الاتاحة: http://ndltd.ncl.edu.tw/handle/squued

المؤلفون: 吴旭 Wu Xu, 沈玉玲 Shen Yuling, 马跃博 Ma Yuebo, 颜坤 Yan Kun, 伍忠东 Wu Zhongdong, 赵汝进 Zhao Ru-jin

المصدر: Acta Optica Sinica. 40:0315002

مصطلحات موضوعية: Computer science, business.industry, Video tracking, Computer vision, Artificial intelligence, business, Atomic and Molecular Physics, and Optics, Electronic, Optical and Magnetic Materials, Term (time)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::8dfebdcd8a417358fcc7165cfec79544
https://doi.org/10.3788/aos202040.0315002

Alternate Title: Effects of root abscisic acid on Na+ transport and photosystem n in Helianthus tuberosus under salt stress. (English)

المؤلفون: 边甜甜, 颜坤, 韩广轩, 安孟鑫, 杨润亚

المصدر: Chinese Journal of Applied Ecology / Yingyong Shengtai Xuebao; Feb2020, Vol. 31 Issue 2, p508-514, 7p

Alternate Title: Research Progress on Precision Application Technology of Biological Control. (English)

المؤلفون: 吴晓青, 赵晓燕, 徐元章, 王加宁, 周方园, 周红姿, 张广志, 谢雪迎, 颜坤, 张新建

المصدر: Journal of Agricultural Science & Technology (1008-0864); 2019, Vol. 21 Issue 3, p13-21, 9p

المؤلفون: 顏坤德

Thesis Advisors: 張勝茂

وصف الملف: 176

الاتاحة: http://ndltd.ncl.edu.tw/handle/71401911730205571420

المؤلفون: 顏坤煌(Kun-Huang Yan), 姚智榮(Yao CJ)*, 張晃猶(Chang HY), 賴基銘(Gi-Ming Lai), 鄭安理(Cheng AL), 莊雙恩(Chuang SE)

المساهمون: 中醫學院中醫學系學士班中醫基礎學科

Relation: http://ir.cmu.edu.tw/ir/handle/310903500/27967

الاتاحة: http://ir.cmu.edu.tw/ir/handle/310903500/27967

المؤلفون: Yan, Kun-Huang, 顏坤煌

Thesis Advisors: Chang, Hwan-You, Chuang, Shuang-En, 張晃猷, 莊雙恩

وصف الملف: 75

الاتاحة: http://ndltd.ncl.edu.tw/handle/77487813141987393975

المؤلفون: Quin-yui Yen, 顏坤昱

Thesis Advisors: John F. An, 安仲芳

وصف الملف: 52

الاتاحة: http://ndltd.ncl.edu.tw/handle/99589786596955061315

المؤلفون: KUN-Ming Yan, 顏坤銘

Thesis Advisors: Kai-Tai Song, 宋開泰

وصف الملف: 52

الاتاحة: http://ndltd.ncl.edu.tw/handle/15240780822665442503

المؤلفون: Kun-Huang Yan, 顏坤煌

Thesis Advisors: Rong-Long Pan, 潘 榮 隆

وصف الملف: 48

الاتاحة: http://ndltd.ncl.edu.tw/handle/24024382287397254074

المؤلفون: 顏坤益

Thesis Advisors: 胡能忠

الاتاحة: http://ndltd.ncl.edu.tw/handle/82825234085078371547

المؤلفون: YAN, KUN-HONG, 顏坤鴻

Thesis Advisors: WANG, WEI-XIN, 王維新

وصف الملف: 81

الاتاحة: http://ndltd.ncl.edu.tw/handle/46280848993604810098

المؤلفون: Yan, Kun-Huang, 顏坤煌

المساهمون: 張晃猷, 莊雙恩, Chang, Hwan-You, Chuang, Shuang-En

مصطلحات موضوعية: 加成作用, 拮抗作用

Time: 5

Relation: 1. Jalving M, Koornstra JJ, De Jong S, De Vries EG, Kleibeuker JH. Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Alimentary pharmacology & therapeutics 2005;21(4):321-339. 2. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. International journal of cancer 2006;118(3):773-779. 3. Keshamouni VG, Reddy RC, Arenberg DA et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004;23(1):100-108. 4. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer research 2000;60(4):1129-1138. 5. Feinstein DL, Spagnolo A, Akar C et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochemical pharmacology 2005;70(2):177-188. 6. Satoh T, Toyoda M, Hoshino H et al. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2002;21(14):2171-2180. 7. Han S, Sidell N, Fisher PB, Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 2004;10(6):1911-1919. 8. Smith MT. Mechanisms of troglitazone hepatotoxicity. Chemical research in toxicology 2003;16(6):679-687. 9. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. The New England journal of medicine 1998;338(13):916-917. 10. Wang PS, Chou FS, Porchia L, Saji M, Pinzone JJ. Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells. Molecular carcinogenesis 2008;47(12):905-915. 11. Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. The Journal of biological chemistry 2003;278(8):5845-5853. 12. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC cancer 2006;6:53. 13. Moysich KB, Menezes RJ, Ronsani A et al. Regular aspirin use and lung cancer risk. BMC cancer 2002;2:31. 14. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J 2001;15(12):2057-2072. 15. di Palma A, Matarese G, Leone V et al. Aspirin reduces the outcome of anticancer therapy in Meth A-bearing mice through activation of AKT-glycogen synthase kinase signaling. Molecular cancer therapeutics 2006;5(5):1318-1324. 16. Kurth T, Hennekens CH, Buring JE, Gaziano JM. Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. Current rheumatology reports 2004;6(5):351-356. 17. Abdin AA, Baalash AA, Hamooda HE. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. Journal of diabetes and its complications 2009. 18. Cui X, Yang SC, Sharma S, Heuze-Vourc'h N, Dubinett SM. IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer. Biochemical and biophysical research communications 2006;343(4):995-1001. 19. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer research 1998;58(2):362-366. 20. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Molecular pharmacology 2007;71(6):1715-1720. 21. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. Faseb J 2006;20(12):2009-2016. 22. Elder DJ, Paraskeva C. COX-2 inhibitors for colorectal cancer. Nature medicine 1998;4(4):392-393. 23. Brenner DE, Gescher AJ. Cancer chemoprevention: lessons learned and future directions. British journal of cancer 2005;93(7):735-739. 24. Stark LA, Reid K, Sansom OJ et al. Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 2007;28(5):968-976. 25. Kim CH, Kim MY, Moon JY et al. Implication of NAG-1 in synergistic induction of apoptosis by combined treatment of sodium salicylate and PI3K/MEK1/2 inhibitors in A549 human lung adenocarcinoma cells. Biochemical pharmacology 2008;75(9):1751-1760. 26. Shaik MS, Chatterjee A, Jackson T, Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. International journal of cancer 2006;118(2):396-404. 27. Xing L, Zhang Z, Xu Y, Zhang H, Liu J. The effects of nimesulide combined with cisplatin on lung cancer. Journal of Huazhong University of Science and Technology Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao 2004;24(2):120-123. 28. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Progress in experimental tumor research Fortschritte der experimentellen Tumorforschung 2003;37:179-192. 29. Yu J, Qiao L, Zimmermann L et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology (Baltimore, Md 2006;43(1):134-143. 30. Liu JJ, Liu PQ, Lin DJ et al. Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro. Annals of hematology 2007;86(3):173-183. 31. Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001;22(9):1379-1383. 32. Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. The Journal of biological chemistry 2001;276(15):12440-12448. 33. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochemical and biophysical research communications 2006;346(1):83-88. 34. Goetze S, Bungenstock A, Czupalla C et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 2002;40(5):748-754. 35. Goetze S, Eilers F, Bungenstock A et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochemical and biophysical research communications 2002;293(5):1431-1437. 36. Colleselli D, Bijuklic K, Mosheimer BA, Kahler CM. Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation. Experimental cell research 2006;312(15):2933-2941. 37. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological reviews 2006;58(3):621-681. 38. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation 1984;22:27-55. 39. Chu YW, Yang PC, Yang SC et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. American journal of respiratory cell and molecular biology 1997;17(3):353-360. 40. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991;27(7):897-900. 41. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. Clinical pharmacokinetics of troglitazone. Clinical pharmacokinetics 1999;37(2):91-104. 42. Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR. Aspirin induces apoptosis through the inhibition of proteasome function. The Journal of biological chemistry 2006;281(39):29228-29235. 43. Frantz B, O'Neill EA. The effect of sodium salicylate and aspirin on NF-kappa B. Science (New York, NY 1995;270(5244):2017-2019. 44. Kwon T, Kwon DY, Chun J, Kim JH, Kang SS. Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. The Journal of biological chemistry 2000;275(1):423-428. 45. Zhang QG, Wang XT, Han D, Yin XH, Zhang GY, Xu TL. Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury. Journal of neurochemistry 2006;98(6):1886-1898. 46. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. The lancet oncology 2004;5(7):419-429. 47. Rumi MA, Ishihara S, Kadowaki Y et al. Peroxisome proliferator-activated receptor gamma-dependent and -independent growth inhibition of gastrointestinal tumour cells. Genes Cells 2004;9(11):1113-1123. 48. Yoshida K, Tanabe K, Fujii D, Oue N, Yasui W, Toge T. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer research 2003;23(1A):267-273. 49. Verheugt FW. Aspirin, the poor man's statin? Lancet 1998;351(9098):227-228. 50. Pawelczyk T, Kloszewska I, Sobow T. [Statins--"21st century aspirin"?]. Pol Merkur Lekarski 2005;19(109):111-114. 51. Sanchez-Alcazar JA, Bradbury DA, Pang L, Knox AJ. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung cancer (Amsterdam, Netherlands) 2003;40(1):33-44. 52. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009. 53. Alfonso LF, Srivenugopal KS, Arumugam TV, Abbruscato TJ, Weidanz JA, Bhat GJ. Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. International journal of oncology 2009;34(3):597-608. 54. Boncler M, Gresner P, Nocun M et al. Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. Biochimica et biophysica acta 2007;1770(12):1651-1659. 55. Chen YC, Shen SC, Tsai SH. Prostaglandin D(2) and J(2) induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochimica et biophysica acta 2005;1743(3):291-304. 56. McInnes C. Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug discovery today 2008;13(19-20):875-881. 57. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. The Biochemical journal 2008;415(3):333-344. 58. Sheng S, Qiao M, Pardee AB. Metastasis and AKT activation. Journal of cellular physiology 2009;218(3):451-454. 59. Kim J, Jonasch E, Alexander A et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009;15(1):81-90. 60. Uruno A, Sugawara A, Kudo M, Satoh F, Saito A, Ito S. Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase. Hypertens Res 2008;31(11):2085-2096. 61. Maddika S, Panigrahi S, Wiechec E et al. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Molecular and cellular biology 2009;29(5):1235-1248. 62. Zhang R, Banik NL, Ray SK. Combination of all-trans retinoic acid and interferon-gamma upregulated p27(kip1) and down regulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (PTEN-proficient) and U87MG (PTEN-deficient) cells. Cancer chemotherapy and pharmacology 2008;62(3):407-416. 63. Wang P, Ma Q, Luo J et al. Nkx3.1 and p27(KIP1) Cooperate in Proliferation Inhibition and Apoptosis Induction in Human Androgen-Independent Prostate Cancer Cells. Cancer investigation 2009:1. 64. Munoz-Alonso MJ, Gonzalez-Santiago L, Zarich N et al. Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells. The Journal of pharmacology and experimental therapeutics 2008;324(3):1093-1101. 65. Xie XH, An HJ, Kang S et al. Loss of Cyclin B1 followed by downregulation of Cyclin A/Cdk2, apoptosis and antiproliferation in Hela cell line. International journal of cancer 2005;116(4):520-525. 66. Yuan J, Yan R, Kramer A et al. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004;23(34):5843-5852. 67. Yang YC, Tsao YP, Ho TC, Choung IP. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer 2007;17(2):418-425. 68. Liou JY, Wu CC, Chen BR, Yen LB, Wu KK. Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway. Molecular pharmacology 2008;74(5):1399-1406. 69. Naito Y, Takagi T, Matsuyama K, Yoshida N, Yoshikawa T. Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats. Alimentary pharmacology & therapeutics 2001;15(6):865-873. 70. Fotoohi AK, Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leukemia & lymphoma 2008;49(3):410-426. 71. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology (Oxford, England) 2007;46(10):1520-1524. 72. Yamauchi A, Ichimiya T, Inoue K et al. Cell-cycle-dependent pharmacology of methotrexate in HL-60. Journal of pharmacological sciences 2005;99(4):335-341. 73. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacological reviews 2005;57(2):163-172. 74. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bulletin of the NYU hospital for joint diseases 2007;65(3):168-173. 75. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. The New England journal of medicine 1985;312(13):818-822. 76. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis research 2002;4(4):266-273. 77. Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis and rheumatism 2007;56(6):1765-1775. 78. Hani N, Casper C, Groth W, Krieg T, Hunzelmann N. Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease. Eur J Dermatol 2000;10(7):548-550. 79. Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis--complicating the treatment of cancer. Neoplasia (New York, NY 2004;6(5):423-431. 80. Tomoda R, Seto M, Hioki Y et al. Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma. Clinical & experimental metastasis 2005;22(7):559-564. 81. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB. Combined methotrexate-PUVA therapy in the treatment of psoriasis. Journal of the American Academy of Dermatology 1982;6(1):46-51. 82. Sweeney CJ, Takimoto CH, Latz JE et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Clin Cancer Res 2006;12(2):536-542. 83. Pablos JL. Aspirin antiplatelet therapy and nonsteroidal antiinflammatory drugs: comment on the 2002 update of the American College of Rheumatology Guidelines for the Management of Rheumatoid Arthritis. Arthritis and rheumatism 2002;46(11):3102. 84. Van Dyke AL, Cote ML, Prysak G, Claeys GB, Wenzlaff AS, Schwartz AG. Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 2008;17(1):148-157. 85. Cuzick J, Otto F, Baron JA et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The lancet oncology 2009;10(5):501-507. 86. Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. The Journal of rheumatology 1995;22(11):2072-2077. 87. Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis and rheumatism 1991;34(12):1514-1520. 88. Fries JF, Singh G, Lenert L, Furst DE. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis and rheumatism 1990;33(11):1611-1619. 89. Rooney TW, Furst DE, Koehnke R, Burmeister L. Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate. The Journal of rheumatology 1993;20(8):1297-1302. 90. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008;9(4):439-451. 91. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004;5(7):819-834. 92. Sowers R, Toguchida J, Qin J et al. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Molecular cancer therapeutics 2003;2(6):535-541. 93. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Molecular and cellular biology 1993;13(3):1610-1618. 94. Yan KH, Yao CJ, Chang HY, Lai GM, Cheng AL, Chuang SE. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Molecular carcinogenesis 2009. 95. Resnitzky D, Hengst L, Reed SI. Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Molecular and cellular biology 1995;15(8):4347-4352. 96. Mateo F, Vidal-Laliena M, Canela N et al. Degradation of cyclin A is regulated by acetylation. Oncogene 2009;28(29):2654-2666. 97. Bock JM, Menon SG, Goswami PC et al. Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Molecular carcinogenesis 2007;46(10):857-864. 98. Janssen A, Maier TJ, Schiffmann S et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. European journal of pharmacology 2006;540(1-3):24-33.; http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/59778

الاتاحة: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/59778

المؤلفون: 顏坤銘, KUN-Ming Yan, 宋開泰, Kai-Tai Song

المساهمون: 電控工程研究所

مصطلحات موضوعية: 家用機器人, 語音辨識, Home Robot, Speech Recognition

Relation: http://140.113.39.130/cdrfb3/record/nctu/#NT900591094; http://hdl.handle.net/11536/69464

الاتاحة: http://hdl.handle.net/11536/69464
http://140.113.39.130/cdrfb3/record/nctu/#NT900591094

المؤلفون: 颜坤志

مصطلحات موضوعية: 热力学性质, 高温空气, 配分函数, 带电粒子, 平衡常数, 平衡成分, 热力学函数, 电子浓度, 双原子分子, thermodynamic property, Partition function, charged particle, Equilibrium constant, thermodynamic function, diatomic molecule, 分拆函数

Relation: 力学进展; 颜坤志. 高温空气的热力学性质[J]. 力学进展,1985,15(4):471-486.; http://dspace.imech.ac.cn/handle/311007/37374

الاتاحة: http://dspace.imech.ac.cn/handle/311007/37374

المؤلفون: 陳光蓉, 楊玲玲, 劉鴻榮, 顏坤熒, KWANG-JONG CHEN, LING-LING YANG, HUNG-JUNG LIU, KUN-YING YEN

المساهمون: 臺北醫學大學

وصف الملف: 21779798 bytes; application/pdf

Relation: http://libir.tmu.edu.tw/handle/987654321/27929; http://libir.tmu.edu.tw/bitstream/987654321/27929/1/Clerodendrum屬民間藥材之生理活性.pdf

الاتاحة: http://libir.tmu.edu.tw/handle/987654321/27929
http://libir.tmu.edu.tw/bitstream/987654321/27929/1/Clerodendrum屬民間藥材之生理活性.pdf

المؤلفون: 楊玲玲, 王正怡, 顏坤熒, 董大成, Ling-Ling Yang, Cheng-Yi Wang, Kun-Ying Yen, Ta-Cheng Tung

المساهمون: 臺北醫學大學

وصف الملف: 21227718 bytes; application/pdf

Relation: http://libir.tmu.edu.tw/handle/987654321/27775; http://libir.tmu.edu.tw/bitstream/987654321/27775/1/中藥增強免疫方劑之臨床評估.pdf

الاتاحة: http://libir.tmu.edu.tw/handle/987654321/27775
http://libir.tmu.edu.tw/bitstream/987654321/27775/1/中藥增強免疫方劑之臨床評估.pdf

المؤلفون: 顏坤益

وصف الملف: 121 bytes; text/html

Relation: http://ir.lib.ntust.edu.tw/handle/987654321/54136; http://ir.lib.ntust.edu.tw/bitstream/987654321/54136/1/index.html

الاتاحة: http://ir.lib.ntust.edu.tw/handle/987654321/54136
http://ir.lib.ntust.edu.tw/bitstream/987654321/54136/1/index.html

المؤلفون: 俞鸿儒, 唐贵明, 李静美, 李仲发, 颜坤志, 马家欢, 唐宗衡

Relation: 俞鸿儒,唐贵明,李静美,等. 激波风洞的应用研究. 全国科学大会奖:大会奖. 1978.; http://dspace.imech.ac.cn/handle/311007/22010

الاتاحة: http://dspace.imech.ac.cn/handle/311007/22010